Sms Pharmaceuticals Limited · NSE:SMSPHARMA
Sms Pharmaceuticals — Q3 FY25 Earnings Presentation
19 slides from Sms Pharmaceuticals's earnings presentation, Feb 12, 2025
Slide 1: Exchange filing cover letter for investor presentation
Date: 12th February, 2025 To, The Manager, The Manager, Corporate Filings Department, Listing Compliance Department, BSE Limited, National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai- 400 001 Mu
Slide 2: Investor Presentation Q3FY25
Investor Presentation Q3FY25 February 2025
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by SMS Pharmaceuticals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Q3FY25 business and financial highlights
Quarterly Performance Review Q3FY25 business and financial highlights • Healthy YoY revenue growth of 7% driven by volume Revenue growth across product portfolio • EBITDA grew 15% YoY with EBITDA margin at 19% vs Profitability 18% a year ago • PAT increased by 59% YoY due to lower finance costs • 2n
Slide 5: Q3FY25 financial highlights
Quarterly Performance Review Q3FY25 financial highlights REVENUE (₹ CRORE) EBITDA (₹ CR) MARGIN (%) PAT (₹ CR) MARGIN (%) EPS (₹) 11% 10% 2.15 246 20% 2.04 1.95 18% 19% 197 16% 1.69 173 14% 7% 7% 7% 1.4 162 164 34 34 33 17 16 18 29 31 14 12 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q3FY24 Q4FY24 Q1FY25 Q2F
Slide 6: Key operating metrics Q3FY25
Quarterly Performance Review Key operating metrics Q3FY25 REVENUE BY THERAPEUTIC AREA (%) REVENUE BY GEOGRAPHY -WISE* 6% 8% (%) 5% 6% 8% 1% 5% 12% 11% 10% 12% 13% 3% 1% 5% 7% 6% 5% 4% 8% 10% 6% 7% 7% 89% 90% 88% 88% 87% 6% 13% 12% 14% 17% 12% Others Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Anti-epileptic
Slide 7: Company Overview
pharmaceuticals Itd. Company Overview
Slide 8: SMS at a Glance: Building a sustainable global business
SMS at a Glance Building a sustainable global business From a single unit-product facility to becoming a diversified API player with a global presence, we have… ⚫ Global and domestic leadership in key APIs ⚫ An integrated business model with accredited facilities ⚫ Strong presence in regulatory mark
Slide 9: 35+ history of delivering value
SMS at a Glance 35+ history of delivering value 1989 1995 2000 2003 2007 Inception Scaling Up Building our USFDA audit IPO-listing SMS Pharma was Became the world’s portfolio • Successful first SMS Pharma got started with a single largest Acquired a facility to USFDA audit listed on NSE and unit-pro
Slide 10: State-of-the-art, accredited manufacturing facilities
Our Strengths State-of-the-art, accredited manufacturing facilities Hyderabad unit Vizag unit Hyderabad Vizag Manufacturing capacity: 120 KL for niche small-volume Manufacturing capacity: 3,000 KL for niche large- molecules volume molecules Regulatory approvals: USFDA,EUGMP, KFDA,CDSCO,PMDA Regulato
Slide 11: Healthy product mix of high-value and high-volume products
Our Strengths Healthy product mix of high-value and high-volume products Therapeutic areas Key products Category High growth products Anti-inflammatory Anti Retro Viral (ARV) Ibuprofen Tenofovir High-volume High-volume 63:37 Sitagliptin, Empagliflozin, Anti-diabetic High-value Dapagliflozin, Vildagl
Slide 12: Strong thrust on R&D
Our Strengths Strong thrust on R&D New product development Added 18 new products Consistent investment in R&D Allocation of 1.5-2% of sales to R&D Strong partnerships JV with Spanish pharma giant Chemo Iberica S.A. Large technical team 60+ scientists Focus on commercialisation 20+ DMFs filed 11
Slide 13: Diversified to mitigate risk and optimise growth
Our Strengths Diversified to mitigate risk and optimise growth GEOGRAPHY THERAPEUTIC AREAS CUSTOMERS 76% 9 7 2 6 25 15 9 23% 14 20 76 17 Largest customer Top 10 customer revenue revenue contribution contribution 87% contribution from regulated markets in FY24 Top five therapies contributed Largest c
Slide 14: Marquee customer base
Our Strengths Marquee customer base 13
Slide 15: Experienced BoD to deliver on strategy
Our Strengths Experienced BoD to deliver on strategy Sri. Ramesh Babu Potluri Sri. Vamsi Krishna Potluri Sri. Shravan Kudravallii Sri. Sarvepalli Srinivas Chairman & Managing Director Executive Director Independent Director Director Sri. Dr. Suresh Kumar Sri. Sunkara Venkata Smt. Shanti Sree Bolleni
Slide 16: Strategies for growth
Way forward Strategies for growth Achieve global scale in • Aim to achieve a production target of 1,000 MT per month ibuprofen Leveraging diversified • Strong presence in both key high-margin and high-volume products portfolio for growth Backward integration to • Vertical integration of select produ
Slide 17: Robust growth is expected in revenue and profitability
Outlook Robust growth is expected in revenue and profitability REVENUE (₹ CR) Key Drivers: 709 563 535 Portfolio approach to drive revenue 520 522 Cost optimisation and enhanced operational efficiency FY21 FY22 FY23 FY24 9MFY25 EBITDA (₹ CR) MARGIN (%) 23% Improved profitability through backward int
Slide 18: Consolidated P&L statement
Financial statements Consolidated P&L statement YoY QoQ YoY Particulars (₹ Cr) Q3FY25 Q3FY24 Growth Q2FY25 Growth 9MFY25 9MFY24 Growth (%) (%) (%) Revenue from Operations 173.35 161.48 7% 196.75 -12% 534.55 463.47 15% COGS 106.24 110.74 -4% 137.69 -23% 350.08 315.16 11% Gross Profit 67.11 50.74 32%
Slide 19: Thank You
Mr. Thirumalesh Tumma Aditya Dutta SMS Pharmaceuticals ltd EQSPONENT Partners LLP complianceofficer@smspharma.com smspharma.ir@eqsponent.com Thank You